Another biotech startup revealed plans Friday evening for an initial public offering, making it the sixth startup to list new ...

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every ...

Gilead’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the reins ...

The US' Health Resources and Services Administration threatened Johnson & Johnson with fines for unilaterally reshaping the ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...

The US Court of Appeals for the Fifth Circuit is reviving PhRMA's legal attack on Medicare drug price negotiations. On Friday ...

This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her ...

Novo Nordisk has ended one of the multiple trials testing the lead oral drug from its $1.1 billion Forma Therapeutics buyout, ...

After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday.